1737-36-6

Basic information

• Product Name: 4-CHLORO-3-(TRIFLUOROMETHYL)BENZOIC ACID
• Synonyms: 4-CHLORO-3-(TRIFLUOROMETHYL)BENZOIC ACID;RARECHEM AL BO 0816;4-Chloro-3-(trifluoromethyl)benzoic acid, 97+%;4-Chloro-3-(trifluoromethyl)benzioc acid;4-Chloro-3-(trifluoromethyl)benzoic acid 97%;5-Carboxy-2-chlorobenzotrifluoride;3-(Trifluoromethyl)-4-chlorobenzoic acid;4-chloro-3-(trifluoroMethyl)
• CAS NO: 1737-36-6
• Molecular Formula: C₈H₄ClF₃O₂
• Molecular Weight: 224.56
• Mol File: 1737-36-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 163-165°C
• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: /
• Density: 1.523
• Vapor Pressure: 0.000984mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.54±0.10(Predicted)
• Water Solubility: Slightly soluble in water at 25°C 0.039 g/L.
• CAS DataBase Reference: 4-CHLORO-3-(TRIFLUOROMETHYL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-3-(TRIFLUOROMETHYL)BENZOIC ACID(1737-36-6)
• EPA Substance Registry System: 4-CHLORO-3-(TRIFLUOROMETHYL)BENZOIC ACID(1737-36-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 1737-36-6(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

Uses

It is used in the synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.

InChI:InChI=1/C8H4ClF3O2/c9-6-2-1-4(7(13)14)3-5(6)8(10,11)12/h1-3H,(H,13,14)/p-1

Upstream product

• 445303-09-3 2-(4-chloro-3-trifluoromethyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2] dioxaborolane 
• 14660-45-8 potassium monomethylcarbonate 
• 1735-54-2 4-chloro-3-(trifluoromethyl)benzonitrile 

Downstream Products

• 115591-64-5 4-chloro-3-trifluoromethylbenzoic acid methyl ester 
• 1298084-30-6 N-(3-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-4-chloro-3-(trifluoromethyl)benzamide 
• 1298083-99-4 N-(3-(1-(6-aminopyrimidin-4-yl)-1H-indol-6-yl)phenyl)-4-chloro-3-(trifluoromethyl)benzamide 
• 1222888-93-8 C₂₄H₁₄ClF₃N₂O₃S 
• 1220701-48-3 (S)-4-chloro-N-(4-(1-(2-((2-hydroxypropyl)amino)pyrimidin-4-yl)-1H-imidazole-2-carbonyl)phenyl)-3-(trifluoromethyl)benzamide 
• 1220701-31-4 C₂₄H₂₀ClF₃N₆O₂ 
• 1220701-22-3 (S)-4-chloro-N-(3-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)-3-(trifluoromethyl)benzamide 
• 1173701-45-5 N-(4-(4-acetamido-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-4-chloro-3-(trifluoromethyl)benzamide 
• 1207608-51-2 C₂₃H₁₅ClF₃N₃O₃ 
• 1207608-47-6 C₂₉H₂₀ClF₃N₄O₂ 
• 1207608-45-4 C₂₂H₁₄ClF₃N₄O₂ 
• 1207608-41-0 C₂₃H₁₅ClF₃N₃O₃ 
• 1192309-51-5 4-Chloro-N-{4-chloro-3-[2-(2-dimethylamino-ethylamino)-8-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide 
• 773134-81-9 ethyl 4-chloro-3-(trifluoromethyl)benzoate 

Relevant articles and documents

Silver-Catalyzed C-H Trifluoromethylation of Arenes Using Trifluoroacetic Acid as the Trifluoromethylating Reagent

Direct trifluoromethylation of arenes using TFA as the trifluoromethylating reagent was achieved with Ag as the catalyst. This reaction not only provides a new protocol for aryl C-H trifluoromethylation, but the generation of CF3· from TFA may prove useful in other contexts and could potentially be extended to other trifluoromethylation reactions. (Chemical Equation Presented).

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.